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Abstract
Background: The additional value of perioperative antibiotic prophylaxis in preventing infectious complications
after emergency cholecystectomy for acute cholecystitis is a much-debated subject in the surgical community.
Evidence-based guidelines are lacking, and consequently the use of antibiotic prophylaxis varies greatly among
surgeons and hospitals. Recently, high-level evidence became available demonstrating that postoperative antibiotic
prophylaxis in patients with acute cholecystitis does not reduce the risk of infectious complications. Preoperative
antibiotic prophylaxis in relation to the risk of infectious complications, however, has never been studied.
Methods: The PEANUTS II trial is a randomized, controlled, multicenter, open-label noninferiority trial whose aim is
to determine the utility of preoperative antibiotic prophylaxis in patients undergoing emergency cholecystectomy
for acute calculous cholecystitis. Patients with mild or moderate acute cholecystitis, as defined according the Tokyo
Guidelines, will be randomly assigned to a single preoperative dose of antibiotic prophylaxis (2000 mg of first-
generation cephalosporin delivered intravenously) or no antibiotic prophylaxis before emergency cholecystectomy.
The primary endpoint is a composite endpoint consisting of all postoperative infectious complications occurring
during the first 30 days after surgery. Secondary endpoints include all the individual components of the primary
endpoint, all other complications, duration of hospital stay, and total costs. The hypothesis is that the absence of
antibiotic prophylaxis is noninferior to the presence of antibiotic prophylaxis. A noninferiority margin of 10% is
assumed. With a 1-sided risk of 2.5% and a power of 80%, a total of 454 subjects will have to be included.
Analysis will be performed according to the intention-to-treat principle.
Discussion: The PEANUTS II trial will provide evidence-based advice concerning the utility of antibiotic prophylaxis
in patients undergoing emergency cholecystectomy for acute calculous cholecystitis.
Trial registration: Netherlands Trial Register, NTR5802. Registered on 4 June 2016.
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Background
Acute calculous cholecystitis is a frequently encoun-
tered disease in surgical practice that generally man-
dates emergency cholecystectomy. Although this is
considered to be a low-risk procedure, the complication
rate is not negligible. The most common complication
is a postoperative infection, either at the surgical site or
a distant site, occurring in approximately 17% of
patients [1]. As such, many patients receive antibiotic
prophylaxis before cholecystectomy, often to be contin-
ued for several postoperative days, in order to reduce
postoperative infectious complications.
The Working Party on Antibiotic Policy in the
Netherlands (Stichting Werkgroep Antibioticabeleid)
issued guidelines for perioperative antibiotic prophy-
laxis in Dutch hospitals [2]. According to these
guidelines, perioperative antibiotic prophylaxis is
recommended for surgical procedures with a moderate
or high risk of postoperative infections, including
biliary surgery. Prophylaxis given within 2 h before inci-
sion appears to be most effective [2]. Recommended is
single-dose prophylaxis, not only because it has proven
to be as effective as multiple-dose prophylaxis but also
for reasons of cost-effectiveness and prevention of bac-
terial resistance. The Surgical Infection Society and the
Infectious Diseases Society of America, as well as the
Tokyo Guidelines, also recommend antimicrobial
prophylaxis for patients undergoing cholecystectomy
for acute cholecystitis [3, 4]. These recommendations,
however, are based on low-quality evidence, and there-
fore the actual effect of perioperative antibiotic prophy-
laxis remains unclear. Consequently, the use of
antibiotic prophylaxis in the treatment of acute chole-
cystitis is highly variable among surgeons and hospitals.
In patients undergoing elective cholecystectomy for
uncomplicated cholelithiasis, high-level evidence is
available demonstrating that prophylactic antibiotics
do not reduce the incidence of postoperative infec-
tions [5–9]. For this indication, the use of periopera-
tive antibiotic prophylaxis is discouraged. According
to a recent randomized controlled trial, also in emer-
gency cholecystectomy the continuation of antibiotic
prophylaxis after surgery is disputable [1]. This study
demonstrated that postoperative antibiotic prophylaxis
(in addition to a single prophylactic dose prior to
surgery) in patients with mild and moderate acute
cholecystitis did not reduce the risk of infectious
complications. Antibiotic prophylaxis after cholecyst-
ectomy for acute cholecystitis may therefore be
omitted. The remaining question is whether a single
preoperative dose of antibiotic prophylaxis is benefi-
cial in patients undergoing emergency cholecystec-
tomy for acute cholecystitis. This has never been
studied.
If the present study demonstrates that omitting anti-
biotic prophylaxis does not increase the postoperative
infection rate, the use of antibiotics for this indication
can be dropped as a whole. If so, the role of antibiotic
prophylaxis in surgery of the entire upper gastrointes-
tinal tract will become questionable. A decrease of anti-
biotic use on such a scale may result in a large reduction
of needless medical activities, costs, and bacterial resist-
ance. The latter is a growing issue in contemporary
medicine and has emerged as one of the eminent public
health concerns nowadays [10].
The Perioperative Antibiotic Use in the Treatment of
Acute Inflammation of the Gallbladder (PEANUTS II)
trial is designed to assess whether preoperative antibiotic
prophylaxis is indicated to prevent postoperative infec-
tious complications in patients undergoing emergency
cholecystectomy for acute calculous cholecystitis. The
hypothesis is that the absence of antibiotic prophylaxis
does not lead to an increase in infectious complications.
Methods
Design
The PEANUTS II trial is a randomized, controlled, mul-
ticenter, open-label noninferiority trial. Patients will be
randomly allocated to receive either no antibiotics or a
single dose of antibiotic prophylaxis before emergency
cholecystectomy (Fig. 1).
Study population
All patients presenting with acute calculous cholecystitis
to one of the participating hospitals will be assessed for
eligibility. Patients are eligible if diagnosed with mild or
moderate acute calculous cholecystitis as defined
Mild or moderate acute 
calculous cholecystitis*
Randomisation
Antibiotic prophylaxis
Emergency cholecystectomy
Infectious complications 
< 30 days
No antibiotic prophylaxis
Emergency cholecystectomy
Infectious complications 
< 30 days
Fig. 1 Flowchart of study outline of included patients. * According
to the severity assessment criteria of the Tokyo Guidelines [11]
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according the Tokyo Guidelines [11] (Table 1). The
inclusion and exclusion criteria are presented in Table 2.
Primary and secondary endpoints
The primary endpoint is a composite endpoint consist-
ing of all postoperative infectious complications occur-
ring during the first 30 days after surgery. Table 3
provides an overview of the definitions. Secondary
endpoints include all the individual components of the
primary endpoint and, in addition, all other complica-
tions, the total postoperative duration of hospital stay,
and the total costs.
Randomization
Patients will be randomly assigned to the treatment
group (antibiotic prophylaxis) or the nontreatment
group (no antibiotic prophylaxis) as shown in the flow-
chart in Fig. 1. Randomization is performed using an on-
line randomization module (ALEA2.2, https://
nl.tenalea.net/amc/ALEA/; Academic Medical Center,
Amsterdam, The Netherlands) and stratified according
to center. Computer-generated permuted block
randomization with varying block sizes is being used
with a maximum block size of six patients. The sequence
of the different blocks is predetermined by an independ-
ent programmer and concealed to all investigators.
Treatment protocol
Preoperative management
To confirm the diagnosis, all patients presenting with
suspected acute calculous cholecystitis will undergo
standard laboratory workup and ultrasound examination
of the abdomen or contrast-enhanced computed tomog-
raphy if ultrasound results are inconclusive. When pa-
tients are eligible for inclusion and informed consent is
obtained, randomization will take place. Patients in the
treatment group will receive 2000 mg of first-generation
cephalosporin administered intravenously 15–30 mi-
nutes before surgery. Patients in the nontreatment group
will not receive any antibiotic prophylaxis. Cholecystec-
tomy should be performed within 24 h after
randomization. Figure 1 demonstrates the study outline
of patient inclusion.
Surgical management
Cholecystectomy will be performed laparoscopically
using the four-trocar technique according to the guide-
lines of the Dutch Society of Surgery, which includes the
critical view of safety techniques [12]. The surgical pro-
cedure will be performed by or under the supervision of
an experienced laparoscopic surgeon.
Postoperative management
Patients will be discharged on the basis of their clinical
condition and at the discretion of the treating physician.
If patients in either group develop infectious complica-
tions, antibiotic therapy will be started. All events will be
recorded.
Data collection and follow-up
Each patient will receive an anonymous study number
that will be used for the study record forms and the
database. On admission, baseline characteristics, includ-
ing age, sex, body mass index, comorbidity, American
Society of Anesthesiologists physical status score, clinical
data (i.e., temperature on admission, white blood cell
count, C-reactive protein, and duration of symptoms),
will be collected and documented by the admitting phys-
ician or (local) study coordinator (Fig. 2). Data regarding
the surgical procedure, including conversion, bile cul-
ture, empyema, bile spill, and the severity of cholecyst-
itis, will be documented by the performing surgeon
immediately after the procedure. On the day of dis-
charge, a case record form will be completed with
Table 1 Diagnostic criteria for acute cholecystitis according to the Tokyo Guidelines [11]
Severity grade Criteria
Mild (grade I) Does not meet the criteria of “severe” or “moderate” acute cholecystitis. Can also be defined as acute
cholecystitis in a healthy patient with no organ dysfunction and mild inflammatory changes in the gallbladder.
Moderate (grade II) Associated with any one of the following conditions:
1. Elevated white blood cell count (>18,000/mm3)
2. Palpable tender mass in the right upper abdominal quadrant
3. Duration of complaints > 72 h
4. Marked local inflammation (gangrenous cholecystitis, pericholecystic abscess,
hepatic abscess, biliary peritonitis, emphysematous cholecystitis)
Severe (grade III) Associated with dysfunction of any of the following organs/systems:
1. Cardiovascular dysfunction (hypotension requiring treatment
with dopamine > 5 μg/kg/minute or any dose of norepinephrine)
2. Neurological dysfunction (decreased level of consciousness)
3. Respiratory dysfunction (PaO2/FiO2 ratio < 300)
4. Renal dysfunction (oliguria, creatinine > 2.0 mg/dl)
5. Hepatic dysfunction (PT-INR > 1.5)
6. Hematological dysfunction (platelet count < 100,000/mm3)
Abbreviations: PaO2/FiO2 Ratio of partial pressure of arterial oxygen to fraction of inspired oxygen, PT-INR Prothrombin time-international normalized ratio
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information on the occurrence of infectious complica-
tions and, if so, the way the infection was objectified and
treated. One week after discharge, the patients will be
called by phone by the study coordinator, and 1 month
after discharge, the patient will be seen in the outpatient
clinic by a surgeon who will complete a questionnaire
on the patient’s clinical condition and the development
of infectious complications. Every 3 months, all entered
data will be checked for completion by the study coord-
inator, and missing data will be collected from the
participating centers.
Safety
A data and safety monitoring board (DSMB) consisting
of three independent members has been appointed to
assess patient safety. The first meeting will take place
after 20 patients are included and subsequently once per
every 50 included patients. The DSMB has unblinded
access to all data.
Adverse events
An adverse event is defined as an undesirable experience
of a subject during the study, regardless of whether it is
considered related to the intervention. Participating
physicians will report all adverse events to the study
coordinator immediately on occurrence. The study
coordinator will list all adverse events and will present
these to the DSMB for every 30 randomized patients. All
adverse events will be reported to the Dutch Central
Committee on Research Involving Human Subjects
using the committee’s online module (http://
www.toetsingonline.nl).
Ethics
The PEANUTS II trial is being conducted in accordance
with the Declaration of Helsinki and Dutch law regard-
ing research involving human subjects (Wet Medisch
Wetenschappelijk Onderzoek met Mensen). The study
protocol (number NL53084.100.15, version 1.0) was
approved by the Medical Research Ethics Committee
(MEC-U) of the St. Antonius Hospital, Nieuwegein, The
Netherlands, on November 24, 2015. Secondary approval
was obtained from the executive boards of all participat-
ing centers. The study protocol was retrospectively regis-
tered (after enrollment of the first participant) with the
Netherlands Trial Register at www.trialregister.nl
(registration number NTR5802) on June 4, 2016. Writ-
ten informed consent will be obtained from each partici-
pant before any trial-related procedures are carried out.
The present study protocol is written according to the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) 2013 statement for reporting a
clinical trial protocol [13]. The SPIRIT checklist is
provided in Additional file 1.
Statistical considerations
Sample size calculation
A recently published randomized controlled trial showed
a postoperative infectious complication rate of 17% in
patients with mild and moderate acute calculous
Table 3 Definitions of various infectious complications
Complication Definition
Superficial
incisional
Localized signs such as redness, pain, heat,
or swelling at the site of the incision or by
the drainage of pus
Deep
incisional
Presence of pus or an abscess, fever with
tenderness of the wound, or separation
of the edges of the incision exposing
the deeper tissues
Organ or space
infection
Fever and/or elevated CRP/WBC count and
intra-abdominal fluid collection visualized by
CT imaging or ultrasound
Pneumonia Coughing or dyspnea, radiography with infiltrative
abnormalities, or elevated infection parameters in
combination with positive sputum culture
Urinary tract
infection
Dysuria, elevated WBC count, and/or presence
of nitrate in urine sediment in combination with
a positive urine culture
Bacteremia Presence of at least one positive hemoccult test
result for the same pathogen
Abbreviations: CRP C-reactive protein, CT Computed tomographic,
WBC White blood cell
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
● Acute calculous cholecystitis, graded as mild or moderatea
according to Tokyo Guidelines [11]
A. Local signs of inflammation and so forth:
1. Murphy’s sign
2. RUQ mass/pain/tenderness
B. Systemic signs of inflammation and so forth:
1. Fever
2. Elevated CRP
3. Elevated WBC count
C. Imaging findings suspect for acute cholecystitis
Definite diagnosis: one positive item in A and one positive item in B
● Patient will undergo cholecystectomy
● < 18 years of age
● Acalculous cholecystitis
● Acute calculous cholecystitis graded as severe according
to Tokyo Guidelines [11]
● Already receiving or needing antibiotics for
a concomitant infection
● Proven allergy to cefazolin
● Pregnancy
● Indication for ERCP on admission
Abbreviations: CRP C-reactive protein, ERCP Endoscopic retrograde pancreaticocholangiography, RUQ Right upper quadrant, WBC White blood cell
aThe diagnostic criteria for mild and moderate acute cholecystitis are shown in Table 1
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cholecystitis undergoing laparoscopic cholecystectomy
[1]. This percentage has been used as the reference
number for the sample size calculations of the
PEANUTS II trial. A noninferiority margin of 10% is
assumed. This figure is based on recommendations of
the U.S. Food and Drug Administration, which recom-
mends 10% for anti-infective trials. With a 1-sided risk
of 2.5% and a power of 80%, a total of 454 subjects will
have to be included in the trial.
Descriptive statistics
Dichotomous data and counts will be presented as
frequencies. Continuous data will be presented as means
with standard deviations or, in cases of skewed distribu-
tion, as medians with interquartile ranges.
Analyses
After the last patient has completed follow-up, raw data
will be presented to an adjudication committee to
determine whether the endpoints meet the protocol-
specified criteria. Each member of the adjudication
committee is blinded to the treatment allocation and
will assess the potential endpoints individually.
Disagreement will be resolved in a plenary consensus
meeting. After consensus is reached on each individual
endpoint for each patient, final analysis will be
performed by an unblinded independent statistician.
This analysis will be performed according to the
intention-to-treat principle, which means that all
randomized patients will be included in their initially
assigned study arm, regardless of adherence to the
protocol.
STUDY PERIOD
Enrolment Allocation
Postoperative 
follow-up
Close-out
TIMEPOINT Pre-operative 0 1 wk 1 mo 1 mo
ENROLMENT
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS
Antibiotic prophylaxis X
No antibiotic prophylaxis X
ASSESSMENTS
Age X
Sex X
Body Mass Index (BMI) X
Comorbidity X
American Society of Anesthesiologists 
(ASA) score
X
Clinical data X
Surgical data X
Infectious complications X X X
Other complications X X X
Duration of hospital stay X X X
Total medical costs X X
Fig. 2 Content for schedule of enrollment, interventions, and assessments according to the Standard Protocol Items: Recommendations for
Interventional Trials statement [13]
Loozen et al. Trials  (2017) 18:390 Page 5 of 7
For nominal data, the chi-square test or Fisher’s
exact test will be used; for continuous data, the
Mann-Whitney U test will be used. Noninferiority will
be demonstrated if the upper limit of the two-sided
95% CI of the difference of the proportion of the
primary endpoint between the two groups is lower
than the noninferiority margin. The effect will be
measured by the absolute risk difference, and the pre-
cision will be quantified by means of the 95% CI. The
formal statistical hypothesis regarding noninferiority
will be tested by the Westlake-Schuirmann test, with
the noninferiority margin set at 10% and a one-tailed
p value < 0.025 considered statistically significant. For
all other tests, a two-tailed p value < 0.050 is consid-
ered statistically significant. In general, for the
primary endpoint, we do not expect data to be
missing; if so, missing data will not be imputed.
Premature termination of the study
The DSMB will perform a formal interim analysis for su-
periority with respect to the primary endpoint when 50%
(n = 227) of the total number of patients have been ran-
domized and have completed the 1-month follow-up. The
Peto approach will be followed, which includes that the
study will be stopped only for benefit or harm in case of a
p value < 0.001 [14]. Because this is the first randomized
trial on this subject and because future treatment policy
will be based on it, this trial will not be stopped for futility.
Feasibility
Recruitment commenced in March 2016 and is antici-
pated to run until March 2019. Currently, patients are
being recruited at seven major teaching hospitals in The
Netherlands. Every 6 months, the inclusion rate will be
assessed. If accrual is too slow, additional centers will be
invited to participate.
Discussion
Whether antibiotic prophylaxis has any additional value
in preventing infectious complications after emergency
cholecystectomy is a much-debated subject in the surgi-
cal community. Evidence-based guidelines are lacking,
and, as a result, the use of antibiotic prophylaxis varies
greatly among surgeons and hospitals. Recently, high-
level evidence became available demonstrating that
postoperative antibiotic prophylaxis (in addition to a
single preoperative dose) does not reduce the risk of
infectious complications [1]. Preoperative antibiotic
prophylaxis in relation to the risk of infectious complica-
tions, however, has never been studied. We therefore
designed the PEANUTS II trial with the aim of deter-
mining the utility of preoperative antibiotic prophylaxis
in patients undergoing emergency cholecystectomy for
acute calculous cholecystitis.
The PEANUTS II trial has a noninferiority design.
The hypothesis is that the absence of antibiotic prophy-
laxis will not lead to an increase of postoperative infec-
tious complications. In the nontreatment group, either
an increase of the infectious complication rate or no ef-
fect will be seen. Because it is very improbable that the
absence of antibiotic prophylaxis will lead to a decrease
of infectious complications, and thus deviation is pos-
sible in only one direction, a noninferiority design is best
suited to answering this primary question.
The best design for a therapeutic trial is a placebo-
controlled, double-blind trial, but because treatment of
acute cholecystitis is often performed in an acute setting
outside regular working hours, such a design is difficult
to organize. Therefore, an open comparative design was
chosen. We believe that blinding and placebo are not of
absolute importance, because the primary outcome of
the study is an objective criterion with a clearly defined
(internationally accepted) definition. In addition, all
potential endpoints will be assessed individually by the
members of the adjudication committee, who are
blinded to the treatment allocation. Only after reaching
consensus on each individual endpoint for each patient
will final analysis be performed by an unblinded
independent statistician.
Patients with grade III (severe) acute cholecystitis are
septic and require antibiotic treatment in addition to
appropriate organ support [11, 15]. This is the rationale
for exclusively including patients with grade I (mild) and
grade II (moderate) acute cholecystitis.
If this study demonstrates that omitting antibiotic
prophylaxis does not increase the postoperative infection
rate in patients with acute cholecystitis, the role of anti-
biotic prophylaxis in surgery of the entire upper gastro-
intestinal tract will become questionable. A decrease in
the use of antibiotics may result in a large reduction of
bacterial resistance, the latter being an increasingly
serious threat to global public health [10].
Trial status
Recruitment commenced in March 2016 and is antici-
pated to run until March 2019. As of August 20, 2017,
158 patients had been randomized, and 7 hospitals were
participating in the trial. The study results will be com-
municated via publication.
Additional file
Additional file 1: SPIRIT (Standard Protocol Items: Recommendations for
Interventional Trials) checklist. (DOCX 51 kb)
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